Search results
From foundational patents to delivery technology, we have pioneered the development of mRNA medicine since our founding. Along the way, we have accumulated a broad collection of patents, with several hundred additional pending patent applications.
The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
- Giuseppe Ciaramella, Sunny Himansu
- 2020
May 12, 2021 · Webs of intellectual property claims underpin the marketing of many vaccines. For example, the underlying technology used to develop a vaccine can be protected by patents, while manufacturing ...
- Mario Gaviria, Burcu Kilic
- 2021
Dec 30, 2020 · The Coronavirus Efficacy (COVE) phase 3 trial was launched in late July 2020 to assess the safety and efficacy of the mRNA-1273 vaccine in preventing SARS-CoV-2 infection. An independent data...
- Lindsey R. Baden, Hana M El Sahly, Brandon J Essink, Karen Kotloff, Sharon Frey, Rick Novak, David D...
- 2021
PMID: 34853416. DOI: 10.1038/d41586-021-03535-x. No abstract available. Keywords: Intellectual-property rights; SARS-CoV-2; Vaccines. MeSH terms. 2019-nCoV Vaccine mRNA-1273* / economics. 2019-nCoV Vaccine mRNA-1273* / genetics. 2019-nCoV Vaccine mRNA-1273* / supply & distribution. Dissent and Disputes* Drug Industry* / economics.
- Heidi Ledford
- 2021
Sep 4, 2020 · The patent clash over the delivery system used in Moderna’s mRNA-1273 vaccine could hamper the biotech’s ability to price the vaccine competitively, as well as affect its margins versus those...
Aug 5, 2020 · … Barney S. Graham. Show authors. Nature 586 , 567–571 ( 2020) Cite this article. 305k Accesses. 932 Citations. 1931 Altmetric. Metrics. A vaccine for severe acute respiratory syndrome...
